IPO Analysis · Mainboard · 8 August 2026

Molbio Diagnostics: a diagnostics company where the government is the customer.

What the company does

Molbio develops and manufactures point-of-care molecular diagnostics. Its Truenat platform is portable, battery-capable PCR testing that runs 43 assays across infectious and non-communicable diseases — designed to work where a full laboratory does not exist.

That is a genuinely differentiated product. The company holds 191 foreign patents, and 136 of its 153 R&D staff are scientists. This is not a trading business dressed as a technology one.

The numbers, and the divergence in them

Revenue grew 41.68% in FY26. Profit grew 18.44%. Margin gave back 223 basis points of the gain it made the year before.

This is the same shape as the Dhoot Transmission divergence, and it is the number worth asking about: growth accelerated sharply while profitability fell. Without the prospectus I cannot yet say whether that is scale-up cost, product mix, or price pressure from a buyer with leverage. That question goes to the top of the list once the RHP is checked.

The risk that defines this business

Government and international aid agencies were 84.56% of FY26 finished-goods revenue. The top ten customers were 83.26%. And 70.20% of finished-goods revenue came from tuberculosis testing alone.

Read those three together. This is a company whose revenue depends on public health procurement budgets, concentrated in a handful of buyers, for largely one disease.

That is not automatically bad. India’s TB elimination programme and global agency funding are large, durable and policy-backed. But it means the demand curve is set in government budget cycles and donor commitments, not in a competitive market. A procurement delay, a tender loss, or a shift in donor priorities moves this P&L directly — and none of those are things the company controls.

Also disclosed: top ten suppliers at 58.52% of raw-material purchases, contingent liabilities of ₹168.74 crore, consolidated borrowings of ₹422.50 crore as at 31 May 2026, and subsidiaries reporting losses and negative operating cash flows.

The anchor book

Thirty-three investors, with two thirds of the allocation going to domestic mutual funds, plus Goldman Sachs, BlackRock and the IFC. The IFC’s presence is worth noting on its own: a development finance institution investing in a diagnostics company serving public health programmes is a coherent fit, not a generalist chasing an allotment.

For scale, Dhoot’s anchor book ran to 72 investors and ₹918.27 crore on a much larger issue. Molbio’s is smaller in absolute terms but proportionally similar as a share of the offer.

Anchor report

Pros and cons

My view: applying

I am applying for the Molbio Diagnostics IPO.

The reasoning: a genuinely differentiated product with a real patent estate and a real scientific team, entering a market with an enormous undiagnosed disease burden, backed by an anchor book of 33 investors where two thirds of the allocation went to domestic mutual funds — alongside Goldman Sachs, BlackRock and the IFC.

The IFC’s participation is worth isolating. A development finance institution investing in a diagnostics company that serves public health programmes is a coherent, informed fit — not a generalist chasing an allotment. That is a better signal than the size of the book.

What I am not applying on

The grey market premium of ₹130, implying roughly 16.1% at the upper band, is a sentiment reading from an unregulated market. It is recorded here as a fact about market chatter, not as a reason. If the GMP were zero, none of the reasoning above would change.

What makes this uncomfortable

Concentration risk in an auto-components business means losing a customer. Here it means a policy change. Government and aid agencies are 84.56% of finished-goods revenue, the top ten customers are 83.26%, and one disease is 70.20%. The demand curve is set in budget cycles and donor commitments, not in a competitive market.

And the divergence in the growth numbers is unexplained: revenue up 41.68%, profit up 18.44%, margin down 223 basis points.

Six things I want from the prospectus

1. Why PAT margin fell 223 basis points while revenue grew 41.68%.
2. Tenure and renewal terms of the government and agency contracts — annual tenders or multi-year commitments?
3. Revenue outside TB, and its growth rate. That is the whole diversification story.
4. Which subsidiaries are loss-making, and whether the losses are narrowing.
5. What the ₹168.74 crore of contingent liabilities relates to.
6. Valuation on FY26 EPS against listed diagnostics peers.

A listing scorecard for this call will be published on 18 August 2026, whatever the outcome.

Not SEBI registered. This is not investment advice. Figures are as disclosed by the company in its IPO materials and the anchor allocation announcement dated August 2026; ratios are my own calculations. Please read the prospectus and do your own research before investing.